The Biosimilars Council’s parent organization, the Association for Accessible Medicines (AAM), is active in promoting education around a variety of topics that relate to its mission of improving access to safe, quality, effective medicine. Below you will find an overview of content published by AAM during the month of August. Additional resources are available on AAM’s website and you can sign-up to automatically receive the latest news on generic and biosimilar medicines by signing up for AAM’s mailing list below.
AAM This Month – August
Prescription Drug Abuse Prevention
The abuse of prescription opioids and stimulants is a serious problem on college campuses. The Association for Accessible Medicines (AAM) has partnered with EVERFI, Inc., a leader in digital learning and prevention education solutions, to offer a digital curriculum to help prevent abuse—free to any college in America. Let your school know this resource is available.
Preserve Patient Access in Trade Agreements
The U.S. is actively negotiating with Mexico and Canada to revise the North American Free Trade Agreement (NAFTA). One of the provisions under discussion would increase brand-name drug exclusivity (monopolies). Imposing additional brand-name drug exclusivity would keep already high brand drug prices out of reach for patients for longer. Take action and contact your member of Congress now.
North American Generic Drugmakers Call for Rejection of New Exclusivity Period for Biologics
August 28, 2018
AAM Statement in Response to FDA’s Competitive Generic Therapy (CGT) Designation
August 8, 2018
Four Reasons Why – The Benefits of AAM Membership
August 30 | Jewel Smith
Here are four reasons why you should make time to be active in the Association for Accessible Medicines (AAM).
Pharmaceutical Patent Abuse: To Infinity and Beyond!
August 7 | Erik Komendant
Our pharmaceutical industry in the United States is predicated on a balance between innovation and access. We are, however, increasingly seeing evidence of how the patent system is being used to tip the balance and delay patient access to a point well beyond what Congress intended.
Patients Can See Their Savings
August 1 | Sara Skubikowski
Patients can now see how much they save by treating their health conditions using generic drugs thanks to new data pulled from this year’s Generic Access and Savings Report in the United States.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accesiblemeds.org.